-- Scott Roberts
WEDNESDAY, Nov. 24 (HealthDay News) -- Axiron has been approved
by the U.S. Food and Drug Administration as the first topical
testosterone solution to be applied to the underarm, makers Eli
Lilly and Acrux said in a news release.
Previously approved forms of testosterone replacement therapy
have included tablets, skin patches, injections and topical gels.
As many as 13 million men aged 45 or older in the United States
have symptoms of low testosterone, including decreased sexual
desire, fatigue, depressed mood and osteoporosis, the companies
Adverse reactions reported during clinical testing of Axiron
included skin reactions, increased red blood cell count, headache,
diarrhea, vomiting and an increase in blood levels of Prostate
Specific Antigen, a screening marker for prostate cancer.
Axiron hasn't been studied in males younger than 18, the drug
The hormone can be transferred to others via close contact.
Unexpected signs of puberty have been reported among young children
accidentally exposed to testosterone. Axiom users should
immediately cover the applied area and wash their hands to help
avoid this possibility, the companies said.
To learn more about testosterone replacement therapy, visit the
National Institute on Aging.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.